PITTSBURGH, Sept. 11, 2014 /PRNewswire-iReach/ -- Today the FDA announced approval of PleximmuneTM
Personalized Medicine For Better Health
-
11, Sep 2014
-
27, Nov 2013
Prognostic cell-based assay predicts acute cellular rejection in pre- and post-transplant testing...
Chethan Ashokkumar1, Rafia Khan1, Kyle A. Soltys1,Geoffrey Bond1, George V. Mazariegos1, Brandon W. Higgs1, Rakesh Sindhi1 INSTITUTIONS (ALL): 1. Children's Hospital of Pgh of UPMC, Pittsburgh, PA, United States. -
11, Nov 2013
Novel antibody-drug conjugates (ADC), some with dual cellular targets, are re
-
3, Nov 2013
The PleximmuneTM test is the first blood test of its kind to predict whether acute cellular rejection will occur in children with liver or intestine transplantation. -
22, Oct 2013
The American Transplant Congress was held between May 18-22 in Seattle this year. The American Transplant Congress is the premier venue for scientific exchange between the various disciplines uniquely involved in solid organ transplantation.
About
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to
- - Assess disease risk for several immunological disorders.
- - Predict the success of a drug for a specific patient.
- - Develop dosing recommendations for new immunological drugs.
Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.
Contact
- +1 (855) 753-9474
- info@plexision.com
- 4424 Penn Ave., #202, Pittsburgh, PA 15224 USA